Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

What this study is testing ClinicalTrials.gov NCT07319975 ↗

Description as written by the study sponsor.

Obesity is a growing global health problem that affects people of all ages. It can lead to serious health issues such as cardiovascular disease, insulin resistance, inflammation, and reduced physical function. New medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide, have been shown to help people lose significant weight. However, some of this rapid weight loss may come from a reduction in muscle mass rather than fat. Losing muscle can lower physical performance, impair metabolic health, and increase the risk of developing sarcopenic obesity. This study aims to compare the effects of pharmacological treatment alone with a combined treatment program that includes both medication and exercise in individuals with obesity. The primary objective is to evaluate how these two approaches influence body composition. The secondary objective is to examine the effects of pharmacological treatment versus combined treatment on cardiometabolic markers, peripheral muscle strength, functional capacity, respiratory function, respiratory muscle performance, and physical activity levels. The study seeks to determine whether adding structured exercise to medication can provide additional health benefits beyond weight loss.

Treatments tested

• Semaglutide Drug

  They will use only semaglutide.

• Tirzepatide Drug

  They will use only tirzepatide.

• Tirzepatide+Exercise Behavioral

  This group will engage in exercise and receive tirzepatide therapy."

• Semaglutide+Exercise Behavioral

  This group will engage in exercise and receive semaglutide therapy."